Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Nucl Med
Huvudupphovsmän: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Materialtyp: Artigo
Språk:Inglês
Publicerad: Society of Nuclear Medicine 2019
Ämnen:
Theranostics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://ncbi.nlm.nih.gov/pubmed/30291194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk